ATAI is a biotechnology company founded in 2018 in response to the clear and growing unmet needs of mental health patients worldwide. atai is dedicated to acquiring, incubating, and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. ATAI’s business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential.
ATAI now has 12 new medical drugs in the pipeline in various stages. We have covered the companies bringing these compounds to market in-depth here.
ATAI Life Sciences Stock
ATAI Life Sciences is set to go public in early 2021 with an expected $1-$2 billion valuation, according to ATAI’s founder, Christian Angermayer. The company recently had a massively oversubscribed Series C.
ATAI’s ticker symbol has yet to be announced. Stay tuned for more updates concerning ATAI’s stock IPO and exchange listing.